Document is current
Any future updates will be listed below
-
Authors
Ramesh, Amrita
Roy, Sobhan
Slezak, Tomasz
Fuller, James
Graves, Hortencia
Mamedov, Murad R.
Marson, Alexander
Kossiakoff, Anthony A.
Adams, Erin J.
-
Funding
Funding for this research was provided by:
NIH/NIGMS (T32GM007281)
Cancer Research Institute (CRI) Irvington Fellowship
Human Vaccines Project Michelson Prize for Human Immunology
NIH (R01-AI155984)
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 13 March 2025
First Online: 9 April 2025
Declarations
:
: A.M. is a co-founder of Arsenal Biosciences, Function Bio, Spotlight Therapeutics, and Survey Genomics, serves on the boards of directors at Function Bio, Spotlight Therapeutics and Survey Genomics, is a member of the scientific advisory boards of Arsenal Biosciences, Function Bio, Spotlight Therapeutics, Survey Genomics, NewLimit, Amgen, Tenaya, and Lightcast owns stock in Arsenal Biosciences, Function Bio, Spotlight Therapeutics, NewLimit, Survey Genomics, Tenaya, and Lightcast and has received fees from Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Amgen, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Survey Genomics, Lightcast, Gilead, Trizell, Vertex, Merck, Genentech, AlphaSights, Rupert Case Management, Bernstein, GLG, ClearView Healthcare Partners, and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead, and Anthem and reagents from Illumina and Genscript. M.M. is an advisor to Laguna Bio. All of the remaining authors declare no conflict of interest.
